Table of Content

1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
          TABLE 1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
          FIGURE 1 MICROBIOME DIAGNOSTICS MARKET SCOPE
           1.3.1 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA 
          FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
                    2.1.2.3 Breakdown of primary interviews
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.2.1.2 Approach 2: Presentations of companies and primary interviews
                    2.2.1.3 Approach 3: Primary research
                    2.2.1.4 Growth forecast
                    2.2.1.5 CAGR projections
                                FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.3 DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 STUDY ASSUMPTIONS 
    2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET
    2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET 
3 EXECUTIVE SUMMARY (Page No. - 43)
    FIGURE 10 MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MICROBIOME DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 MICROBIOME MARKET OVERVIEW 
          FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022) 
          FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT 
          FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
    4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX 
          FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 MICROBIOME DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of chronic diseases
                                FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045
                    5.2.1.2 Collaborative efforts between microbiome industry and academia for microbiome research
                    5.2.1.3 Growing demand for personalized medicine
                    5.2.1.4 Rising awareness about importance of human microbiomes
                    5.2.1.5 Rising funding and investments in microbiome research
           5.2.2 RESTRAINTS
                    5.2.2.1 End-user budget constraints in developing countries
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased collaboration between key players and small innovative companies to work on new microbiome technologies
                                TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET
           5.2.4 CHALLENGES
                    5.2.4.1 Adverse impact of complex regulatory policies on commercialization of microbiome
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.5 PORTER’S FIVE FORCES ANALYSIS 
           5.5.1 THREAT OF NEW ENTRANTS
           5.5.2 INTENSITY OF COMPETITIVE RIVALRY
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 BARGAINING POWER OF SUPPLIERS
           5.5.5 THREAT OF SUBSTITUTES
    5.6 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS
           5.6.2 BUYING CRITERIA
                    FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
    5.7 REGULATORY LANDSCAPE 
           5.7.1 NORTH AMERICA
                    TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.7.2 EUROPE
                    TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.7.3 ASIA PACIFIC
                    TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.7.4 REST OF THE WORLD
                    TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.8 ECOSYSTEM ANALYSIS 
          TABLE 8 ROLE IN ECOSYSTEM
          FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET
    5.9 PATENT ANALYSIS 
    5.10 KEY CONFERENCES & EVENTS 
           TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023–2024
    5.11 PRICING ANALYSIS 
           5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
                     TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD)
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.13 TECHNOLOGY ANALYSIS 
           5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES
    5.14 TRADE ANALYSIS 
           TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
           TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
6 MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 69)
    6.1 INTRODUCTION 
          TABLE 13 MICROBIOME DIAGNOSTICS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 KITS & REAGENTS 
           6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
                    TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH
                    TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 MICROBIOME DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 73)
    7.1 INTRODUCTION 
          TABLE 16 MICROBIOME DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 16S RRNA SEQUENCING 
           7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING
                    TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
    7.3 SHOTGUN METAGENOMICS 
           7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND
                    TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING
                    TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021–2028 (USD MILLION)
    7.4 METATRANSCRIPTOMICS 
           7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH
                    TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION)
    7.5 OTHER TECHNOLOGIES 
          TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 MICROBIOME DIAGNOSTICS MARKET, BY SAMPLE (Page No. - 78)
    8.1 INTRODUCTION 
          TABLE 22 MICROBIOME DIAGNOSTICS INDUSTRY, BY SAMPLE, 2021–2028 (USD MILLION)
    8.2 FECAL SAMPLES 
           8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
                    TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES
                    TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021–2028 (USD MILLION)
    8.3 SALIVA SAMPLES 
           8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH
                    TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES
                    TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021–2028 (USD MILLION)
    8.4 SKIN SAMPLES 
           8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET
                    TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES
                    TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER SAMPLES 
          TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES
          TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
9 MICROBIOME DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 83)
    9.1 INTRODUCTION 
          TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 DISEASE DIAGNOSTIC APPLICATIONS 
          TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
           9.2.1 GASTROINTESTINAL DISORDERS
                    9.2.1.1 Growing incidence of gastrointestinal disorders to drive market growth
                                TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
           9.2.2 METABOLIC DISORDERS
                    9.2.2.1 High prevalence of metabolic disorders to drive demand for microbiome-based diagnostic products
                                TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
           9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS
                    TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
    9.3 RESEARCH APPLICATIONS 
           9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET
                    TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 MICROBIOME DIAGNOSTICS MARKET, BY END USER (Page No. - 89)
     10.1 INTRODUCTION 
             TABLE 38 MICROBIOME DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022
                        TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
     10.3 RESEARCH INSTITUTES 
             10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH
                        TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS
                        TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
11 MICROBIOME DIAGNOSTICS MARKET, BY REGION (Page No. - 93)
     11.1 INTRODUCTION 
             TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 28 NORTH AMERICA: MICROBIOME DIAGNOSTICS MARKET SNAPSHOT
             TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 US to account for largest share of during forecast period
                                      TABLE 50 US: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 High prevalence of diseases in Canada to support market growth
                                      TABLE 56 CANADA: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             TABLE 62 EUROPE: MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 68 EUROPE: MICROBIOME DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Germany to dominate European microbiome diagnostics market during forecast period
                                      TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Growing number of microbiome sequencing start-ups to boost market growth
                                      TABLE 75 FRANCE: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Supportive environment for microbiome sequencing R&D to support growth
                                      TABLE 81 UK: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 REST OF EUROPE
                        TABLE 87 REST OF EUROPE: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                        TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 92 REST OF EUROPE: MICROBIOME DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 29 ASIA PACIFIC: MICROBIOME DIAGNOSTICS MARKET SNAPSHOT
             TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Collaborations between academic institutes and private companies to drive growth
                                      TABLE 100 CHINA: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Rising aging population to drive market growth
                                      TABLE 106 JAPAN: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing prevalence of diseases to drive market growth
                                      TABLE 112 INDIA: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                                      TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 117 INDIA: MICROBIOME DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 118 REST OF ASIA PACIFIC: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                        TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 ASIA PACIFIC: RECESSION IMPACT
     11.5 REST OF THE WORLD 
             TABLE 124 REST OF THE WORLD: MICROBIOME DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 REST OF THE WORLD: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 134)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS
     12.3 REVENUE ANALYSIS 
             FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS
     12.4 MARKET SHARE ANALYSIS 
             TABLE 131 MICROBIOME DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 31 MICROBIOME DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX
             12.5.5 COMPANY FOOTPRINT ANALYSIS
                        TABLE 132 COMPANY FOOTPRINT
                        TABLE 133 COMPANY PRODUCT FOOTPRINT
                        TABLE 134 COMPANY REGIONAL FOOTPRINT
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 32 MICROBIOME DIAGNOSTICS INDUSTRY: START-UP/SME EVALUATION MATRIX, 2022
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 135 MICROBIOME DIAGNOSTICS INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
     12.7 COMPETITIVE SCENARIO & TRENDS 
             12.7.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 136 MICROBIOME DIAGNOSTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS, 2020–2023
             12.7.2 DEALS
                        TABLE 137 MICROBIOME DIAGNOSTICS INDUSTRY: DEALS, 2020–2023
13 COMPANY PROFILES (Page No. - 147)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 GENETIC ANALYSIS AS
                        TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
                        FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
             13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
                        TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
                        FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
             13.1.3 MICROBA LIFE SCIENCES
                        TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
                        FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
             13.1.4 ILLUMINA INC.
                        TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
                        FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
             13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
                        TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
                        FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
             13.1.6 BIOME OXFORD LTD.
                        TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
             13.1.7 VIENNALAB DIAGNOSTICS GMBH
                        TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
             13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
                        TABLE 145 METABIOMICS: COMPANY OVERVIEW
             13.1.9 VIOME LIFE SCIENCES
                        TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
             13.1.10 LUXIA SCIENTIFIC
                        TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
             13.1.11 SUN GENOMICS
                        TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
             13.1.12 ATLAS BIOMED
                        TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
             13.1.13 QUANTBIOME, INC. (DBA OMBRE)
                        TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
             13.1.14 BECTON, DICKINSON AND COMPANY
                        TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             13.1.15 DAYTWO
                        TABLE 152 DAYTWO: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 MICRONOMA
             13.2.2 TERAOMICS S.L.
             13.2.3 FLIGHTPATH BIOSCIENCES
             13.2.4 MICROBIOME RESEARCH PVT. LTD.
             13.2.5 ORIGIN SCIENCES
             13.2.6 LEUCINE RICH BIO PRIVATE LIMITED
             13.2.7 DECODE AGE
             13.2.8 EVVY
             13.2.9 ALPHABIOMICS, LTD.
             13.2.10 GOODGUT
14 APPENDIX (Page No. - 178)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS